Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.48 |
| ▸ | ITGAV | P06756 | 20/20 | 0.48 |
| ▸ | ITGB5 | P18084 | 19/20 | 0.48 |
| ▸ | ITGB1 | P05556 | 12/20 | 0.48 |
| ▸ | ITGB6 | P18564 | 12/20 | 0.48 |
| ▸ | ITGB8 | P26012 | 11/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20481216 | 0.90 | ITGAV (0.53) | ITGB3ITGAVITGB5ITGB1ITGB6 | |
| SCHEMBL22008992 | 0.90 | ITGAV (0.53) | ITGB3ITGAVITGB5ITGB1ITGB6 | |
| SCHEMBL22008997 | 0.90 | ITGAV (0.53) | ITGB3ITGAVITGB5ITGB1ITGB6 | |
| SCHEMBL23788752 | 0.87 | ITGAV (0.42) | ITGB3ITGAVITGB5ITGB1ITGB6 | |
| SCHEMBL22008596 | 0.79 | ITGAV (0.56) | ITGB3ITGAVITGB5ITGB1ITGB6 | |
| SCHEMBL20481219 | 0.79 | ITGAV (0.56) | ITGB3ITGAVITGB5ITGB1ITGB6 | |
| SCHEMBL22008586 | 0.79 | ITGAV (0.56) | ITGB3ITGAVITGB5ITGB1ITGB6 | |
| SCHEMBL20480966 | 0.77 | ITGAV (0.51) | ITGB3ITGAVITGB5ITGB1ITGB6 | |
| SCHEMBL22008551 | 0.77 | ITGAV (0.51) | ITGB3ITGAVITGB5ITGB1ITGB6 | |
| SCHEMBL22008552 | 0.77 | ITGAV (0.51) | ITGB3ITGAVITGB5ITGB1ITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157075-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157075-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | ITGB3 11/4885ITGAV 3/4885ITGB5 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.